MultiCell Technologies Inc (MCET)

[medspot]

I did notice the extra shares listed as well, but I agree that that just means more funding. I would have expected a slow run up to Tuesday, but the extra shares explain why it's been flat. To not see it go down is encouraging though and I still think that PR news will still cause it to pop... it may not go as high as it would have with the old number of shares outstanding, but IMO it'll still do pretty well next week.

The USPTO issuance of the notification seems standard. The one for the stem cell patent came out weeks before the PR (and formal patent issue) on May 31. The company probably wouldn't feel comfortable with a PR until it is formally granted the patent (7/26)...

I'm surprised that you don't see the patents having any real importance to the value of MCET at this time. For small companies without marketed products, IP is everything! I do agree that they will hold off on development until patents are obtained.

To be realistic, MCET will almost definitely not be taking the stent to late-stage trials on their own, but will instead partner with a bigger company that can afford to do so and is looking for the next generation of "new and improved" stents with lower rates of restenosis and inflammation, and improved remodeling. Again, the patents are the most valuable asset that MCET will have in negotiating an agreement with a potential partner IMO.

Good luck next week everybody!